The effect of SGLT2 inhibitors on hyperglycaemia, insulin resistance, foam cell formation, and cholesterol uptake have all been evaluated in animal models to inform a growing understanding of mechanisms linking SGLT2 inhibitors to reduced ASCVD events. The gene discussed is SLC5A2; the disease is atherosclerosis.